Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 10/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.48 |
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CEPT1 | Q9Y6K0 | 2/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6138783 | 0.89 | SMN1; SMN2 (0.47) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6139058 | 0.84 | SMN1; SMN2 (0.50) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138749 | 0.84 | SMN1; SMN2 (0.56) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138743 | 0.84 | SMN1; SMN2 (0.56) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138844 | 0.84 | SMN1; SMN2 (0.56) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138505 | 0.77 | NPC1 (0.53) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138500 | 0.77 | NPC1 (0.53) | TP53SMN1; SMN2RAB9AHPGDALDH1A1 | |
| SCHEMBL6138359 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9AALDH1A1NPC1KDM4E | |
| SCHEMBL6138741 | 0.77 | HDAC6 (0.59) | TP53SMN1; SMN2RAB9ANPC1CEPT1 | |
| SCHEMBL6138798 | 0.77 | HDAC6 (0.59) | TP53SMN1; SMN2RAB9ANPC1CEPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | claimed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | claimed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | claimed |
| EP-1215203-B1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2004-10-28 | — | — | US | disclosed |
| US-6770644-B1 | Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-08-03 | — | — | US | disclosed |
| EP-1215203-A1 | HYDROXAMIC ACID DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214896-A1 | Hydroxamic acid derivatives, the methods for preparation thereof and pharmaceutical compositions comprising thereof, as an active ingredient | HIF1AN, IL6, PYGM | TP53 748/4885SMN1; SMN2 1536/4885RAB9A 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.